Mandate

Vinge has acted as advisor to APG Asset Management in their investment in Areim Fund II

October 10, 2012

Vinge has acted as advisor to APG Asset Management in their investment in Areim Fund II, a real estate fund mainly focusing on office properties in larger Swedish cities. Areim Fund II has a target of commitments of SEK 2.5 billion upon final closing, which would give Areim Fund II around SEK 6-7 billion to invest.

APG has EUR 314 billion in assets under management (approximately 30% of the collective pension schemes in the Netherlands).

Vinge has about 50 lawyers focusing on private equity, of which approximately 12 are active within fund establishment (with competence within tax, corporate, M&A and finance law). Vinge has for several years been active in fund establishment and was e.g. the advisor to the first fund established in the form of a limited liability company in Sweden. Vinge has since then been involved in the majority of fund establishments in this form.

Partner in charge was Christina Kokko assisted by project manager Johan Steen and associate Jonatan Lund Kirkhoff.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026